---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dual endothelin angiotensin receptor antagonists"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dual endothelin angiotensin receptor antagonists. Topics: Sparsentan indication, dosing, and REMS; Sparsentan versus irbesartan in FSGS: DUPLEX results in the label; Sparsentan versus irbesartan in FSGS: DUPLEX primary publication; Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/dual-endothelin-angiotensin-receptor-antagonists"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dual endothelin angiotensin receptor antagonists

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Dual Endothelin Angiotensin Receptor Antagonists

<a id="topic-2.2.2.1.5-1"></a>

### Sparsentan indication, dosing, and REMS

> “To reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome (1.2, 12.1, 14.2).”
> “FILSPARI is only available through a restricted distribution program called the FILSPARI Risk Evaluation and Mitigation Strategies (REMS) because of the risk of hepatotoxicity (5.2):”
> “Prior to initiating treatment with FILSPARI, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists (ERAs) (2.1, 4, 7.1).”
> “Greater than 50 kg: Initiate treatment with FILSPARI at 400 mg orally once daily. After 14 days, increase to 800 mg once daily, as tolerated (2.4).”

Source: [FDA FILSPARI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216403s006lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Sparsentan versus irbesartan in FSGS: DUPLEX results in the label

> “At baseline, the mean age of trial participants was 42 years (range 9 to 75 years); 54% were male; 73% were White, 13% Asian, 7% Black or African American, and 7% were other, multiple or unknown.”
> “The primary efficacy endpoint at the final analysis was not statistically significant.”
> “In the subgroup of patients without nephrotic syndrome, the percent UPCR reduction at Week 108 from baseline was 48% in patients randomized to FILSPARI compared to 27% in patients randomized to irbesartan.”
> “In contrast, there was no difference between treatment arms in UPCR reduction from baseline to Week 108 in the subgroup of patients with nephrotic syndrome.”

Source: [FDA FILSPARI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216403s006lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Sparsentan versus irbesartan in FSGS: DUPLEX primary publication

> “At 36 weeks, the percentage of patients with partial remission of proteinuria was 42.0% in the sparsentan group and 26.0% in the irbesartan group (P = 0.009), a response that was sustained through 108 weeks.”
> “Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan.”

Source: [Rheault et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37921461/)

<a id="topic-2.2.2.1.5-4"></a>

### Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis

> “Finally, 14 patients (4%) had two APOL1 high-risk alleles, nine in the sparsentan and five in the irbesartan groups.”
> “Sparsentan treatment resulted in profound (approximately 50%) sustained reduction of UPCR in the patients with APOL1 high-risk genotypes, although the treatment effect versus irbesartan was not sustained during the second year of the treatment period (Figure 1C).”
> “CR occurred exclusively in sparsentan-treated patients among those with podocyte gene variants (8% versus 0%), in 18% versus 7% of patients with COL4A3–5 gene variants, and in 33% versus 20% of patients with APOL1 high-risk genotypes.”
> “Owing to the small sample size in each genetic subgroup, the result has limited analytic power”

Source: [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/)

| Subgroup | Sparsentan, time-averaged change from baseline in UPCR, % (95% CI) | Irbesartan, time-averaged change from baseline in UPCR, % (95% CI) | Relative change, % (95% CI) | P value |
| --- | --- | --- | --- | --- |
| APOL1 high-risk genotypes | “−54.3 (−76.6 to −10.9)” | “−33.8 (−71.2 to 52.2)” | “−27.3 (−78.1 to 141.2)” | “0.57” |

Source: [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
